Prostate cancer: Novel genetic and immunologic biomarkers.

Autor: Samare-Najaf M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Kouchaki H; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Moein Mahini S; Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran., Saberi Rounkian M; Student Research Committee, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran., Tavakoli Y; Department of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran., Samareh A; Department of Clinical Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran., Karim Azadbakht M; Sirjan School of Medical Sciences, Sirjan, Iran., Jamali N; Department of Laboratory Sciences, Sirjan School of Medical Sciences, Sirjan, Iran. Electronic address: jamali_navid@yahoo.com.
Jazyk: angličtina
Zdroj: Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2024 Mar 01; Vol. 555, pp. 117824. Date of Electronic Publication: 2024 Feb 03.
DOI: 10.1016/j.cca.2024.117824
Abstrakt: Prostate cancer (PCa) is considered one of the most prevalent male malignancies worldwide with a global burden estimated to increase over the next two decades. Due to significant mortality and debilitation of survival, early diagnosis has been described as key. Unfortunately, current diagnostic serum-based strategies have low specificity and sensitivity. Histologic examination is invasive and not useful for treatment and monitoring purposes. Hence, a plethora of studies have been conducted to identify and validate an efficient noninvasive approach in the diagnosis, staging, and prognosis of PCa. These investigations may be categorized as genetic (non-coding biomarkers and gene markers), immunologic (immune cells, interleukins, cytokines, antibodies, and auto-antibodies), and heterogenous (PSA-related markers, PHI-related indices, and urinary biomarkers) subgroups. This review examines current approaches and potential strategies using biomarker panels in PCa.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: